Alector (ALEC) | Financial Analysis & Statements
Alector Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
6.2M
Operating Income
-39.6M
-634.38%
Net Income
-37.3M
-597.51%
EPS (Diluted)
$-0.34
Balance Sheet Metrics
Total Assets
293.2M
Total Liabilities
262.6M
Shareholders Equity
30.6M
Debt to Equity
8.57
Cash Flow Metrics
Operating Cash Flow
-48.7M
Free Cash Flow
-41.7M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Alector Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 21.0M | 100.6M | 97.1M | 133.6M | 207.1M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 123.1M | 185.9M | 192.1M | 210.4M | 189.4M |
| Selling, General & Administrative | 54.0M | 59.6M | 56.7M | 61.0M | 55.0M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 177.1M | 245.6M | 248.8M | 271.5M | 244.4M |
| Operating Income | -156.0M | -145.0M | -151.7M | -137.8M | -37.4M |
| Operating Margin % | -741.3% | -144.2% | -156.3% | -103.2% | -18.0% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | 13.2M | 26.1M | 26.6M | 7.8M | 1.0M |
| Pre-tax Income | -142.8M | -118.9M | -125.2M | -130.1M | -36.3M |
| Income Tax | 168.0K | 128.0K | 5.2M | 3.3M | 0 |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -142.9M | -119.0M | -130.4M | -133.3M | -36.3M |
| Net Margin % | -679.2% | -118.4% | -134.3% | -99.8% | -17.5% |
| Key Metrics | |||||
| EBITDA | -146.3M | -136.2M | -142.9M | -129.4M | -29.0M |
| EPS (Basic) | $-1.39 | $-1.23 | $-1.56 | $-1.62 | $-0.45 |
| EPS (Diluted) | $-1.39 | $-1.23 | $-1.56 | $-1.62 | $-0.45 |
| Basic Shares Outstanding | 102998978 | 96588177 | 83733730 | 82467587 | 80416936 |
| Diluted Shares Outstanding | 102998978 | 96588177 | 83733730 | 82467587 | 80416936 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Alector Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 65.8M | 33.0M | 74.6M | 154.3M | 329.2M |
| Short-term Investments | 190.2M | 380.4M | 474.3M | 558.5M | 406.1M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | 10.4M | 11.4M | 16.9M | 11.0M | 7.1M |
| Total Current Assets | 266.5M | 424.8M | 565.8M | 726.4M | 749.7M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 32.3M | 38.8M | 43.7M | 45.0M | 44.6M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 2.2M | 6.4M | 9.0M | 7.9M | 7.0M |
| Total Non-Current Assets | 26.8M | 43.5M | 56.0M | 61.2M | 64.9M |
| Total Assets | 293.2M | 468.3M | 621.8M | 787.6M | 814.7M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 1.7M | 2.2M | 3.8M | 4.2M | 4.7M |
| Short-term Debt | 9.4M | 8.8M | 8.5M | 8.1M | 7.8M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 69.5M | 125.1M | 177.9M | 93.8M | 139.6M |
| Non-Current Liabilities | |||||
| Long-term Debt | 26.8M | 33.8M | 30.5M | 35.3M | 39.8M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 1.7M | 1.2M | 1.4M | 759.0K | 158.0K |
| Total Non-Current Liabilities | 193.1M | 216.4M | 309.7M | 479.4M | 374.4M |
| Total Liabilities | 262.6M | 341.5M | 487.7M | 573.2M | 513.9M |
| Equity | |||||
| Common Stock | 11.0K | 9.0K | 8.0K | 8.0K | 8.0K |
| Retained Earnings | -972.1M | -829.1M | -710.1M | -579.7M | -446.4M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 30.6M | 126.8M | 134.2M | 214.4M | 300.7M |
| Key Metrics | |||||
| Total Debt | 36.2M | 42.5M | 38.9M | 43.3M | 47.6M |
| Working Capital | 196.9M | 299.8M | 387.9M | 632.6M | 610.2M |
Balance Sheet Composition
Alector Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -142.9M | -119.0M | -130.4M | -133.3M | -36.3M |
| Depreciation & Amortization | 9.7M | 8.8M | 8.8M | 8.5M | 8.3M |
| Stock-Based Compensation | 26.7M | 39.5M | 42.8M | 46.1M | 40.8M |
| Working Capital Changes | -73.5M | -151.1M | -94.4M | 66.1M | 280.2M |
| Operating Cash Flow | -179.8M | -221.8M | -173.2M | -12.6M | 292.9M |
| Investing Activities | |||||
| Capital Expenditures | -41.0K | -1.3M | -2.4M | -4.1M | -3.2M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -271.9M | -467.7M | -551.7M | -556.9M | -343.4M |
| Investment Sales | 468.5M | 576.1M | 656.0M | 402.0M | 297.0M |
| Investing Cash Flow | 196.6M | 107.1M | 101.9M | -159.0M | -49.7M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 0 | 9.4M | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 20.0M | 80.5M | - | 0 | 0 |
| Free Cash Flow | -184.1M | -231.2M | -186.5M | -24.4M | 295.3M |
| Net Change in Cash | 36.7M | -34.2M | -71.3M | -171.6M | 243.3M |
Cash Flow Trend
Alector Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-1.73
Forward P/E
-2.76
Price to Book
8.74
Price to Sales
12.74
PEG Ratio
0.00
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-587.53%
Return on Equity
-181.56%
Return on Assets
-25.13%
Financial Health
Current Ratio
3.83
Debt to Equity
118.22
Beta
0.58
Per Share Data
EPS (TTM)
$-1.39
Book Value per Share
$0.28
Revenue per Share
$0.20
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ALEC | 266.0M | -1.73 | 8.74 | -181.56% | 0.00% | 118.22 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
| Amylyx | 1.9B | 2.54 | 6.31 | -61.59% | 0.00% | 1.95 |
Financial data is updated regularly. All figures are in the company's reporting currency.






